ERBB2 and breast carcinoma: Given the varying clinical implications and prevalence of TILs across breast cancer subtypes [42], we performed a refined correlation analysis separately for Luminal A, Luminal B, and Her2+/Triple-negative patients using continuous immune marker scores.